2Department of Biology, College of Sciences, Shiraz University
3Shiraz university of Medical Sciences
Cataract is multi-factorial eye disease identified by the disturbance of the transparent ocular lens. There is significant evidence suggesting oxidative damage as a major cause of initiation and progression of numerous diseases including cataracts. NAD(P)H:quinone oxidoreductase 1 (NQO1; OMIM: 125860) and catalase (CAT, OMIM: 115500) are antioxidant enzymes that prevent cells from oxidative stress. The aim of the present study was to investigate the association between NQO1 C609T (Pro189Ser, rs1800566) and CAT promoter C-262T (rs1001179) genetic polymorphisms and the susceptibility to cataracts. A case-control study including 190 cataracts cases and 190 healthy subjects was carried out. Genotype distributions of NQO1 and CAT polymorphisms were examined using polymerase chain reactions and a restriction fragment length polymorphism (PCR-RFLP) approach to investigate the possible role of these polymorphisms as risk factors in the development of cataracts. Variant CT heterozygous and TT genotypes of the NQO1 C609T polymorphism were found to be associated with an increased risk of cataracts (CT vs CC, OR=1.61, 95%CI: 1.02-2.52, P=0.038), (CT/TT vs CC, OR=1.56, 95%CI: 1.02-2.4, P=0.040). In addition, compared to indoor work places and the CC genotype of NQO1, outdoor work places and CT/TT genotypes of NQO1 were found to increase the risk of age-related cataracts (OR=2.75, 95%CI: 1.20-6.33, P=0.017). The analysis did not reveal, however, any statistically significant (P>0.05) difference between CAT C-262T polymorphism and the risk of cataracts.
1. Zheng Y, Liu Y, Ge J, Wang X, Liu L, Bu Z, Liu P. Resveratrol protects human lens epithelial cells against H2O2- induced oxidative stress by increasing catalase, SOD-1, and HO-1 expression. Mol Vis 2010;16:1467-1474.
2. Qian W, Shichi H. Naphthoquinone-induced cataract in mice: Possible involvement of Ca21 release and calpain activation. J Ocul Pharmacol Ther 2001;17:383-392.
3. McCarty CA, Taylor HR. A review of the epidemiologic evidence linking ultraviolet radiation and cataracts. Dev Ophthalmol 2002;35:21-31.
4. Sameer AS, Shah ZH, Syeed N, Abdullah S, Rasool R, Afroze D, Siddiqi MA. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and colorectal cancer predisposition in the ethnic Kashmiri population. Asian Pac J Cancer Prev2010;11:209-213.
5. Zhang J, Li Y, Wang R, Geddert H, Guo W, Wen D, Chen Z, Wei L, Kuang G, He M, Zhang L, Wu M, Wang S. NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China. World J Gastroenterol 2003;9:1390-1393.
6. Li G, Liu Z, Sturgis EM, Chamberlain RM, Spitz MR, Wei Q. CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 2005;14:1034-1036.
7. Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 2010;501:116-123.
8. Yu H, Liu H, Wang L, Wei Q. A functional NQO1 609C.T polymorphism and risk of gastrointestinal cancers: a meta-analysis. Plos One 2012;7:1-11.
9. Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, Ross D. NAD(P)H:Quinone oxidoreductase 1: role as a superoxide scavenge. Mol Pharmacol 2004;65:1238-1247.
10. Siegel D, Mcguinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999;9:113-121.
11. Ahn J, Nowell S, McCann SE. Associations between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol Biomarkers Prev 2006;6:1217-1222.
12. Saadat I, Ahmadi Z, Farvardin-Jahromi M, Saadat M. Association between cataract and genetic polymorphisms of GSTM1, GSTT1, and GSTO2 with respect of work place. Mol Vis 2012;18:1996-2000.
13. Mohamadynejad P, Saadat M. Genetic polymorphisms of XRCC1 (at codons 194 and 399) in Shiraz population (Fars province, southern Iran). Mol Biol Rep 2008;35: 669-672.
14. Saadat M. Distribution of ACE insertion/deletion (I/D) polymorphism in Iranian populations. Mol Biol Res Commun 2015;4:63-66.
15. Newton CR. Mutational analysis: Known mutations. In: McPherson MJ, Hames D, Taylor GR, editors. PCR2. A Practical Approach. Oxford: IRL Press 1995; pp: 219-222.
16. Ebrahimpour S, Saadat I. Association of CAT C-262T and SOD1 A251G single nucleotide polymorphisms susceptible to gastric cancer. Mol Biol Res Commun 2014;3:223-229.
17. Xu LL, Wain JC, Miller DP, Thurston SW, Su L, Lynch TJ, Christiani DC. The NAD(P)H: quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev 2001;10:303-309.
18. Smith MT, Wang Y, Kane E, Rollinson S, Wiemels JS, Roman E, Roddam PH, Cartwright R, Morgan G. Low NAD(P)H: quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 2001;97:1422-1426.
19. Clairmont A, Sies H, Ramachandran S, Lear JT, Smith AG, Bowers B, Jones PW, Fryer AA, Strange RC. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multi variate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis 1999;20:1235-1240.
20. Lafuente MJ, Casterad X, Trias M, Ascaso C, Molina R, Ballesta A, Zheng S, Wiencke JK, Lafuente A. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 2000;21:1813-1819.
21. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 2003;536:131-137.
22. Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M, Ambrosone CB. Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol 2004;3:615-620.